ChemicalBook >> CAS DataBase List >>Crenolanib

Crenolanib

CAS No.
670220-88-9
Chemical Name:
Crenolanib
Synonyms
596;CS-72;CP-868;RO 002;ARO 002;CP868569;CP 868596;Crenolanib;Crenolanib, >=98%;CP868569/Crenolanib
CBNumber:
CB02582957
Molecular Formula:
C26H29N5O2
Molecular Weight:
443.54
MDL Number:
MFCD21609260
MOL File:
670220-88-9.mol
Last updated:2023-05-18 11:31:14

Crenolanib Properties

Boiling point 676.6±65.0 °C(Predicted)
Density 1.36
storage temp. -20°
solubility Soluble in DMSO (up to 15 mg/ml) or in Ethanol (up to 10 mg/ml).
form solid
pka 9.84±0.20(Predicted)
color White
Stability Stable for 1 year as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month.
CAS DataBase Reference 670220-88-9
FDA UNII LQF7I567TQ
NCI Drug Dictionary crenolanib

Crenolanib price More Price(28)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 18873 Crenolanib ≥95% 670220-88-9 1mg $47 2024-03-01 Buy
Cayman Chemical 18873 Crenolanib ≥95% 670220-88-9 5mg $104 2024-03-01 Buy
Cayman Chemical 18873 Crenolanib ≥95% 670220-88-9 10mg $182 2024-03-01 Buy
Cayman Chemical 18873 Crenolanib ≥95% 670220-88-9 50mg $564 2024-03-01 Buy
Usbiological 007102 Crenolanib 670220-88-9 5mg $496 2021-12-16 Buy
Product number Packaging Price Buy
18873 1mg $47 Buy
18873 5mg $104 Buy
18873 10mg $182 Buy
18873 50mg $564 Buy
007102 5mg $496 Buy

Crenolanib Chemical Properties,Uses,Production

Description

Crenolanib (670220-88-9) is a potent inhibitor of PDGFR (Kd?for α = 2.1 nM; β = 3.2 nM) and FLT3 (Kd?= 0.74 nM).1?Crenolanib is a type I inhibitor binding only to the active kinase conformation. It showed potent activity against imatinib-resistant PDGFRα mutations D842I, D842V, D842Y, DI842-843M, and deletion I8432?as well as FLT3/ITD and FLT3/D835 mutants3. Crenolanib acted synergistically with FLT3-CAR T-cells in a FLT3-ITD+?AML murine xenograft model.4

Uses

Crenolanib is an orally bioavailable, selective inhibitor of type III tyrosine kinases with nanomolar potencies against platelet-derived growth factor receptor α (PDGFRα) and PDGFRβ and Fms-related tyrosine kinase 3 (FLT3; IC50s = 11, 3.2, and 4 nM, respectively). It also inhibits medically-relevant mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations. Crenolanib is more than 100-fold selective for these kinases over other tyrosine and serine/threonine kinases. It is effective when used in cells and in vivo.[Cayman Chemical]

Uses

Crenolanib (CP-868569) is a tyrosine kinase inhibitor that acts by specifically inhibiting the receptor tyrosine kinases PDGFRα and PDGFRβ. Crenolanib (CP-868569) inhibits the activity of PDGFRα D842V kinase and prevented the phosphorylation of wild type PDGFRα. Crenolanib (CP-868569) possesses potential antineoplastic activity. Crenolanib is believed to suppress PDGFR-related signal transduction pathways leading to the inhibition of tumor angiogenesis and tumor cell proliferation.

Uses

Crenolanib (CP-868569) is a highly selective and potent PDGFR-α inhibitor with IC50 of 0.9 and 1.8 nM against PDGFRα and PDGFRβ, respectively.

Definition

ChEBI: Crenolanib is a member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a 8-(4-aminopiperidin-1-yl)quinolin-2-yl group at position 1 and by a (3-methyloxetan-3-yl)methoxy group at position 5. It is an inhibitor of type III tyrosine kinases, PDGFRalpha/beta and FLT3 (IC50 of 11, 3.2, and 4 nM). Currently under clinical development for the treatment of acute myeloid leukemia. It has a role as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, an angiogenesis inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of benzimidazoles, an aromatic ether, a member of quinolines, a member of oxetanes, an aminopiperidine and a tertiary amino compound.

target

PDGFRα

References

1) Lewis?et al.?(2009)?Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers; J. Clin. Oncol.?27?5262 2) Smith?et al.?(2014)?Crenolanib is a selective type I pan-FLT3 inhibitor; Proc. Natl. Acad. Sci. USA?111?5319 3) Heinrich?et al.?(2012)?Crenolanib Inhibits Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors; Clin. Cancer Res.?18?4375 4) Jetani?et al.?(2018)?CAR T-cells targeting FLT3 have potent activity against FLT-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib; Leukemia?32?1168

Crenolanib Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 128)Suppliers
Supplier Tel Email Country ProdList Advantage
career henan chemical co
+86-0371-86658258 sales@coreychem.com China 29914 58
Biochempartner
0086-13720134139 candy@biochempartner.com CHINA 967 58
Hubei xin bonus chemical co. LTD
86-13657291602 linda@hubeijusheng.com CHINA 22968 58
Chongqing Chemdad Co., Ltd
+86-023-61398051 +8613650506873 sales@chemdad.com China 39916 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000 marketing@targetmol.com United States 19892 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250 1026@dideu.com China 29220 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471 sales@sarms4muscle.com China 10523 58
InvivoChem
+1-708-310-1919 +1-13798911105 sales@invivochem.cn United States 6393 58
ZHEJIANG JIUZHOU CHEM CO., LTD
+86-0576225566889 +86-13454675544 admin@jiuzhou-chem.com;jamie@jiuzhou-chem.com;alice@jiuzhou-chem.com China 20000 58
Zhengzhou Anbu Chem Co.,Ltd
+86-0371-88006763; +8615988602810 sales@anbuchem.com China 3000 58

View Lastest Price from Crenolanib manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Crenolanib pictures 2019-07-06 Crenolanib
670220-88-9
US $7.00 / KG 1KG 99% 100KG Career Henan Chemical Co
  • Crenolanib pictures
  • Crenolanib
    670220-88-9
  • US $7.00 / KG
  • 99%
  • Career Henan Chemical Co

Crenolanib Spectrum

Crenolanib, >=98% Crenolanib [1-[2-[5-(3-Methyloxetan-3-ylMethoxy)benziMidazol-1-yl]quinolin-8-yl]piperidin-4-yl]aMine 1-[2-[5-[(3-Methyl-3-oxetanyl)Methoxy]-1H-benziMidazol-1-yl]-8-quinolinyl]-4-piperidinaMine ARO 002 CP 868596 Crenolanib (CP-868569) Crenolanib (CP-868596) CP868569/Crenolanib cp-868596 crenolanib 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1H-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine Crenolanib ,ARO 002 1-(2-(5-((3-Methyloxetan-3-yl)methoxy)-1H-benzo-[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-ami 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1-benzimidazolyl]-8-quinolyl]-4-piperidinamine CS-72 596 CP-868 CP-868;596; CP-868596; ARO 002;CP868596 CP868569 CRENOLANIB;CP-868596;CP 868596;ARO 002 4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]- Crenolanib USP/EP/BP RO 002 670220-88-9 Inhibitors Aromatics Heterocycles Intermediates & Fine Chemicals Pharmaceuticals Tyrosine Kinase Inhibitors